- Work/Life Balance
- Culture & Values
- Career Opportunities
- Comp & Benefits
- Senior Management
NGM Bio’s comprehensive approach to drug discovery focuses on elucidating the biology of hormones, cell receptors and associated ligands. As we investigate these novel biological mechanisms, we assemble a deep understanding of the relationship between the structure and function of proteins of interest. Coupled with our experience in protein and antibody engineering, our approach enables the efficient and targeted generation of potential first-in-class therapeutics with optimized pharmacologic profiles.
NGM Bio’s initial R&D focus has been to develop a portfolio of high-impact therapeutics for the underserved patient populations who suffer from cardio-metabolic and liver diseases. We believe that our research expertise – comprehensive and grounded in fundamental, interrelated mechanisms of human biology – is capable of driving the development of new therapies for a wide range of other disease areas as well, such as cancer.
Learn about our pipeline.
At NGM Bio, we offer a creative, collaborative, highly challenging scientific environment where innovation and cutting-edge science is the foundation for a robust, drug discovery engine. We are seeking collaborative colleagues who are forward and innovative thinkers, willing to push the boundaries of knowledge and science, and thrive on the challenges presented by a dynamic drug discovery and development organization that is passionate about improving patient lives.
Biology Driven. NGM Bio’s in-depth biology-based approach to drug discovery is designed to identify therapeutics that address the fundamental mechanisms underlying disease states. Research Driven. Our portfolio consists of clinical and preclinical development programs, focusing on cardio-metabolic and liver diseases, and immuno-oncology. People Driven. Our experienced and passionate scientific team has joined forces with distinguished researchers and prominent industry professionals.
NGM Bio is located in South San Francisco where we are surrounded by an entrepreneurial and creative spirit. From recent grads to experienced PhDs, we are seeking candidates who share our passion and commitment. NGM Bio is an equal-opportunity employer and offers a strong compensation package that includes salary, stock options, 401(k), and a comprehensive benefits package.
Interested applicants should apply through the NGM Bio website.
Mr. Rieflin joined NGM as Chief Executive Officer in 2010 and brings over 20 years of industry experience to the company. Most recently, he was President of XenoPort, Inc. (NASDAQ: XNPT). Prior to that, he was Executive Vice President, Administration, Chief Financial Officer, General Counsel and Secretary for Tularik Inc. (NASDAQ: TLRK), which was acquired by Amgen Inc. in 2004. Previously, he was Vice President, Human Resources, General Counsel and Secretary for AMSCO International, Inc. (NYSE: ASZ). He was also an associate at Sidley & Austin in the corporate and securities department. He began his career as a sales representative for American Hospital Supply Corporation. He currently serves on the Board of Directors of Anacor Pharmaceuticals, Inc. (NASDAQ: ANAC), FLX Bio, Inc. and XenoPort. Mr. Rieflin earned his B.S. from Cornell University, his M.B.A. from the University of Chicago Booth School of Business and his J.D. from Stanford Law School.
Prior to joining NGM in 2014, Mr. Jonker was the Senior Vice President, Corporate and Business Development at Theravance Biopharma (NASDAQ: TBPH) and held that same role at Theravance, Inc. (NASDAQ: THRX) prior to the spin-out of TBPH. He previously served as the Chief Business Officer of Satori Pharmaceuticals, the Vice President of Business Development and Corporate Strategy for Gloucester Pharmaceuticals prior to its acquisition by Celgene (NASDAQ: CELG) and leadership positions in the business development and legal groups at Genentech. Prior to Genentech, he was an associate in the Technology Transactions Group at Wilson, Sonsini, Goodrich & Rosati, representing clients in the life science and high tech industries. Mr. Jonker holds a J.D. from Columbia University School of Law, an M.LITT. from the University of St. Andrews and a B.A. from Claremont McKenna College.
Dr. Chen is the Company's Founder, and has served as a member of the board of directors and as the Chief Scientific Officer since January 2008. He was also NGM's President until November 2014. Previously, Dr. Chen held various positions at Amgen, most recently as its Vice President, Metabolic Disorders, with responsibility for leading the company's global research efforts in small molecule and biologic drug discovery for the treatment of human diseases affecting metabolism, bone, mineral balance and muscle. Prior to joining Amgen, he served as Vice President of Biology at Tularik where he guided drug discovery research in oncology, inflammation and metabolic disease. Dr. Chen's pioneering work on a broad array of targets at both Amgen and Tularik not only opened up opportunities to study new aspects of biology and physiology across disease areas, but also led to contributions of multiple drug candidates to the development pipelines of these organizations, including RepathaTM (evolocumab), a novel anti-PCSK9 antibody that lowers low-density lipoprotein cholesterol.
Dr. Chen received a B.S. in Nutrition and Food Science from Fu-Jen Catholic University, and a M.S. in biochemistry from National Taiwan University. He completed his graduate training at the University of California, Berkeley in 1994, receiving a Ph.D. for his research on the mechanisms of transcription carried out in the laboratory of Prof. Robert Tjian.
Prior to joining NGM in 2010, Dr. DePaoli was CMO at InteKrin Therapeutics. In this role he oversaw global development of INT131, a PPARg modulator, through a successful End of Phase 2 meeting with the FDA. He brings to NGM more than 20 years of experience as a clinician and translational researcher in diabetes, obesity and metabolic disease. Dr. DePaoli trained in Clinical and Molecular Endocrinology at the University of Chicago and in the Howard Hughes laboratory of Dr. Graham Bell. His clinical and translational research interests in diabetes and obesity were focused during his work at the Sansum Diabetes Research Institute which led him to join Amgen in 1998 to champion the development of their cardiometabolic disease portfolio. His work at Amgen was pivotal in enabling multiple clinical applications of the adipocytokine leptin (Myalept). At Amgen, he also led a broad array of cardiometabolic, muscle and bone programs with a focus on translating novel pathways into the clinic. These pathways included: RANK Ligand (now Prolia and Xgeva), PCSK9 (Evolocumab), 11 Beta HSD-1, Myostatin, IL-1 receptor, Calcium Sensing Receptor (Sensipar), PPAR-gamma modulation, DPP-4 and MCH-R1. Dr. DePaoli also maintains a clinical endocrinology practice at the William Sansum Diabetes Center.
Dr. Trombley joined NGM as head of Business Development in 2011 and became our Vice President, Chief Operating Officer in 2015. She was most recently from Novartis in Basel, Switzerland, where she was Chief of Staff for the Chief Executive Officer and worked on key corporate initiatives and strategic projects across the company’s healthcare businesses. Previously, she was Associate Director, Business Development at XenoPort, Inc. (NASDAQ: XNPT), where her responsibilities also included strategic and portfolio planning in addition to various out-licensing projects. Prior to XenoPort, she was a Senior Engagement Manager at McKinsey & Company, where she advised pharmaceutical and medical device clients on strategic, commercial and operational issues. She received a B.S. in Chemistry from the University of California, San Diego and a Ph.D. in Chemistry from MIT.
Dr. Woodhouse joined NGM in 2015 from Goldman Sachs where he was a managing director and co-head of U.S. biotechnology investment banking. As a member of Goldman's healthcare investment banking group for nearly 13 years in both the New York and San Francisco offices, his responsibilities included corporate finance and mergers and acquisitions advice for the biotechnology, specialty pharma and diagnostics industries. In this capacity, he advised on several billion in equity and equity-linked financings as well as over $90 billion in M&A transactions.
Prior to Goldman Sachs, Dr. Woodhouse worked in various business development and research roles at Dynavax and Amgen. He graduated, with highest honors, from UC Santa Barbara, with a B.A. in Pharmacology. He also earned a Ph.D. in Molecular Pharmacology from Stanford University School of Medicine and an M.B.A. from the Tuck School of Business at Dartmouth.
"I enjoy working with smart people and this is the brightest group I’ve ever worked with! They keep me smart and on my toes. They inspire me and they motivate me to work my brain harder than I imagined possible.”
"I don’t like to sit idle. I like to work hard and work with like-minded people who are doers. In most companies, if you see a ball on the floor, the average person will step right over it. At NGM, we pick up that ball and do something with it. NGM is a very proactive community."
“My projects at NGM are both interesting and fun and I work here because I love the work! I was a surgeon in China, which to me was a perfect job, and I can't practice surgery here; so this is the next best thing…. the perfect job in the States!”
Small environment with great workers.
Can improve communication to teams.
I applied through other source. The process took 3 weeks. I interviewed at NGM Biopharmaceuticals (South San Francisco, CA) in August 2017.
I was lucky enough to know somebody who knew somebody at NGM. My resume was then passed along to a hiring manager, who I then spoke to over the phone. Maybe a week later, I did a Skype video interview with the manager, a director, and several other people over the course of 90 minutes. They liked me enough to invite me for an onsite interview, which was a week later.
The interview process was an all day affair. I first met with HR to go over HR kind of stuff, then I proceeded to give a presentation to a room full of scientists and associates. It seem to go over very well, and pertinent questions were asked. I then interviewed with scientists and associates over the course of 5 more hours. I had lunch with several associates, and they also gave me a tour of the labs - which were great, btw. The interview closed with a nice long chat with the hiring manager. Unfortunately, I never got an offer from them - I would have loved working for NGM. Everyone was extremely nice, I loved the work space areas, the labs, and especially the hiring manager and director. Most importantly, the people there really believed in the company and the company's mission, which was fantastic. I wish them all the best in the future.
Pledge to Thrive
Taking steps to prioritize employee well-being